Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Ramin Oskoui

Cardiovascular Disease Washington, DC Medical Doctor

NPI 1457306805 CMS profile 65238

3301 New Mexico Ave Nw, #316, Washington, DC 20016

Open in the dashboard

General payments

$15,305

414 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Ramin Oskoui of Washington, DC is reported in the CMS Open Payments database as having received $15,305 across 414 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $344 17
2022 General $2,517 71
2021 General $2,311 99
2020 General $2,697 116
2019 General $7,436 111

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ramin Oskoui
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Ramin Oskoui were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Ramin Oskoui Cardiovascular Disease median Middle half National median
2019 $7,436 $450 $127–$1,392 $163
2020 $2,697 $242 $77–$751 $114
2021 $2,311 $335 $101–$1,037 $132
2022 $2,517 $395 $121–$1,211 $149
2023 $344 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Medtronic Vascular, Inc. $3,662 68 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $3,630 28 payments
  3. Medtronic, Inc. $1,193 37 payments
  4. Pfizer Inc. $1,134 38 payments
  5. Amgen Inc. $597 23 payments
  6. Novo Nordisk Inc $591 13 payments
  7. Novartis Pharmaceuticals Corporation $560 33 payments
  8. Sanofi-Aventis U.S. LLC $488 33 payments
  9. AstraZeneca Pharmaceuticals LP $465 12 payments
  10. Esperion Therapeutics, Inc. $461 15 payments
  11. Other $2,523 114 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $10,172 399 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,805 1 payment
  3. Travel and Lodging $1,975 3 payments
  4. Education $352 11 payments
Products named General payments · program years 2019–2023
  1. PRADAXA $3,120 13 payments
  2. ELIQUIS $844 31 payments
  3. JARDIANCE $695 25 payments
  4. Claria MRI $611 5 payments
  5. Repatha $597 23 payments
  6. ENTRESTO $539 32 payments
  7. NEXLETOL $461 15 payments
  8. VYNDAQEL $396 21 payments
  9. MICRA $349 13 payments
  10. LifeVest $324 15 payments
  11. Other $6,038 274 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

414 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record